Correction to: Leukemia advance online publication 13 January 2017; doi:10.1038/leu.2016.388
Following the publication of this article, it was noted that the HTML version contained the wrong AAP date. The correct AAP date is 27 December 2016.
Additional information
The online version of the original article can be found at 10.1038/leu.2016.388
Rights and permissions
About this article
Cite this article
Hipp, S., Tai, YT., Blanset, D. et al. Erratum: A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31, 2278 (2017). https://doi.org/10.1038/leu.2017.219
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.219
This article is cited by
-
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma
Nature Communications (2024)
-
Immunotherapy in AL Amyloidosis
Current Treatment Options in Oncology (2022)
-
Emerging agents and regimens for multiple myeloma
Journal of Hematology & Oncology (2020)
-
What is new in the treatment of Waldenstrom macroglobulinemia?
Leukemia (2019)
